Realtime-Estimate
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
1’588 GBX | -0.14% | -2.58% | +9.43% |
Kurzporträt
Mitarbeiterzahl: 70 212
Umsatz nach Geschäftsbereich
GBP in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
Commercial Operations
100,0
%
| 29 324 | 100,0 % | 30 328 | 100,0 % | +3.42% |
Umsatz je Region
GBP in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
United States
52,2
%
| 14 542 | 49,6 % | 15 820 | 52,2 % | +8.79% |
Rest of World
45,6
%
| 14 087 | 48,0 % | 13 815 | 45,6 % | -1.93% |
United Kingdom
2,3
%
| 695 | 2,4 % | 693 | 2,3 % | -0.29% |
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Emma Walmsley
CEO | Chief Executive Officer | 55 | 01.05.10 |
Julie Brown
DFI | Director of Finance/CFO | 62 | 01.05.23 |
James Ford
CMP | Compliance Officer | - | 01.08.95 |
Amy Altshul
CTO | Chief Tech/Sci/R&D Officer | - | - |
Chief Tech/Sci/R&D Officer | - | 01.01.18 | |
Tony Wood
CTO | Chief Tech/Sci/R&D Officer | - | 01.08.17 |
Hal Barron
BRD | Director/Board Member | 62 | 01.01.18 |
David Redfern
PRN | Corporate Officer/Principal | 57 | 01.01.94 |
Frannie DeFranco
PRN | Corporate Officer/Principal | - | 01.09.10 |
Claire Lund
PRN | Corporate Officer/Principal | - | - |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Julie Brown
DFI | Director of Finance/CFO | 62 | 01.05.23 |
Jonathan Symonds
CHM | Chairman | 66 | 01.09.19 |
Urs Rohner
BRD | Director/Board Member | 65 | 01.01.15 |
Hal Barron
BRD | Director/Board Member | 62 | 01.01.18 |
Vishal Sikka
BRD | Director/Board Member | 57 | 18.07.22 |
Wendy Becker
BRD | Director/Board Member | 58 | 01.10.23 |
Charles Bancroft
BRD | Director/Board Member | 65 | 01.05.20 |
Emma Walmsley
CEO | Chief Executive Officer | 55 | 01.05.10 |
Director/Board Member | 66 | 01.09.22 | |
Jesse Goodman
BRD | Director/Board Member | 72 | 01.01.16 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 4 400 765 312 | 4 074 081 600 ( 92,58 %) | 255 885 366 ( 5,815 %) | 92,58 % |
Unternehmensbesitz
Name | Aktien | % | Bewertung |
---|---|---|---|
127 054 524 | 75,00% | 2 960 098 513 $ | |
HALEON PLC 4,22% | 385 320 110 | 4,22% | 1 621 384 638 $ |
VIR BIOTECHNOLOGY, INC. 6,33% | 8 550 954 | 6,33% | 86 621 164 $ |
WAVE LIFE SCIENCES LTD. 11,44% | 13 983 761 | 11,44% | 86 279 805 $ |
263 029 794 | 82,59% | 80 253 020 $ | |
HALEON PAKISTAN LIMITED 85,79% | 100 423 259 | 85,79% | 70 443 903 $ |
LYELL IMMUNOPHARMA, INC. 11,91% | 30 253 189 | 11,91% | 67 464 611 $ |
CUREVAC N.V. 7,41% | 16 591 937 | 7,41% | 50 273 569 $ |
GLAXOSMITHKLINE S.A.E 91,20% | 76 161 378 | 91,20% | 48 251 279 $ |
DONG-A ST CO., LTD. 8,38% | 722 016 | 8,38% | 39 741 046 $ |
Unternehmenskontakt
Konzerngesellschaften
Name | Kategorie und Branche |
---|---|
GlaxoSmithKline Capital Plc
|
Finance/Rental/Leasing
|
GlaxoSmithKline Biologicals NV
GlaxoSmithKline Biologicals NV BiotechnologyHealth Technology GlaxoSmithKline Biologicals SA manufactures vaccines for diseases such as hepatitis, influenza, rubella, and typhoid fever. Its activities include overall strategy, research and development, clinical trials, regulatory matters, production, quality control, marketing, and distribution. The company has partnership with WHO and UNICEF. GlaxoSmithKline Biologicals was founded in 1945 and is headquartered in Rixensart, Belgium. |
Biotechnology
|
Eskaylab Ltd.
Eskaylab Ltd. Miscellaneous Commercial ServicesCommercial Services Founded in 1908, Eskaylab Ltd. is a testing British laboratory company that operates in Middlesex, UK. |
Miscellaneous Commercial Services
|
Horlicks Ltd.
Horlicks Ltd. Beverages: AlcoholicConsumer Non-Durables Horlicks Ltd. manufactures and distributes infant food products. The products it offers are Horlicks traditional, light and light chocolate. The company was founded on December 11, 1925 and is headquartered in Brentford, the United Kingdom. |
Beverages: Alcoholic
|
Novartis Consumer Health SA
Novartis Consumer Health SA Pharmaceuticals: MajorHealth Technology Part of GSK Plc, Novartis Consumer Health SA is a private company based in Basel, Switzerland. |
Pharmaceuticals: Major
|
Glaxo Group Ltd.
Glaxo Group Ltd. Pharmaceuticals: MajorHealth Technology Founded in 1935, Glaxo Group Ltd. is a subsidiary of GSK Plc. The private company is based in Middlesex, UK. At GSK, we unite science, technology and talent to get ahead of disease together. |
Pharmaceuticals: Major
|
GlaxoSmithKline Finance Plc
|
Finance/Rental/Leasing
|
Setfirst Ltd.
Setfirst Ltd. Financial ConglomeratesFinance Part of GSK Plc, Setfirst Ltd. functions as an investment holding British company. The private company is based in Middlesex, UK. |
Financial Conglomerates
|
GlaxoSmithKline GmbH & Co. KG
GlaxoSmithKline GmbH & Co. KG Pharmaceuticals: MajorHealth Technology Part of GSK Plc, GlaxoSmithKline GmbH & Co. KG is a German pharmaceutical company. The private company is based in Munich, Germany. The CEOs of the company are Jean-Bernard Siméon, Adrian Bauer. |
Pharmaceuticals: Major
|
Sektor
Umsatz nach Geschäftsbereich
Umsatz je Region
Verlauf des Gewinns je Aktie
% 1. Jan. | Kap. | |
---|---|---|
+9.43% | 80.88 Mrd. | |
+28.79% | 676 Mrd. | |
+24.11% | 554 Mrd. | |
-7.64% | 349 Mrd. | |
+15.00% | 318 Mrd. | |
+5.99% | 291 Mrd. | |
+3.17% | 210 Mrd. | |
-0.29% | 204 Mrd. | |
-9.65% | 194 Mrd. | |
-11.71% | 144 Mrd. |
- Börse
- Aktien
- A3DMB5 Aktie
- Unternehmen GSK plc